Skip to main content

Table 2 Correlation between FGFR1 gene amplification and the clinicopathological variables

From: FGFR1 amplification in breast carcinomas: a chromogenic in situhybridisation analysis

Parameter

Number of samples

Positive FGFR1 amplification number (%)

P value

Age

478

 

0.027

   <50 years

152

7 (4.6)

 

   ≥50 years

346

35 (10.1)

 

Grade

478

 

Not significant

   1

116

10 (8.6)

 

   2

141

12 (8.5)

 

   3

221

20 (9.0)

 

Size

478

 

Not significant

   ≥1.5 cm

311

30 (9.6)

 

   >1.5 cm

167

12 (7.2)

 

Lymph node stage

475

 

Not significant

   N0

322

28 (8.7)

 

   N1

110

9 (8.2)

 

   N2

43

4 (9.3)

 

Nottingham Prognostic Index

475

 

Not significant

   Good

175

14 (8.0)

 

   Moderate

239

21 (8.8)

 

   Poor

61

6 (9.8)

 

Distant metastasis

478

 

0.050

   No

394

30 (7.6)

 

   Definite

84

12 (14.3)

 

Vascular invasion

467

 

Not significant

   No

337

27 (8.0)

 

   Yes

130

14 (10.8)

 

Oestrogen receptor

453

 

Not significant

   Negative

140

10 (7.1)

 

   Positive

313

27 (8.6)

 

Progesterone receptor

449

 

0.084

   Negative

206

22 (10.7)

 

   Positive

243

15 (6.2)

 

HER2

445

 

0.043

   Negative

259

28 (10.8)

 

   Positive

186

10 (5.4)

 

Androgen receptor

415

 

Not significant

   Negative

188

18 (9.6)

 

   Positive

227

13 (5.7)

 

Cytokeratin 7/8

467

 

Not significant

   Negative

167

17 (10.2)

 

   Positive

300

24 (8.0)

 

Cytokeratin 18

396

 

Not significant

   Negative

116

7 (6.0)

 

   Positive

280

23 (8.2)

 

Cytokeratin 19

464

 

Not significant

   Negative

95

10 (10.5)

 

   Positive

369

30 (8.1)

 

Cytokeratin 5/6

465

 

Not significant

   Negative

350

34 (9.7)

 

   Positive

115

6 (5.2)

 

Cytokeratin 14

458

 

Not significant

   Negative

357

33 (9.2)

 

   Positive

101

6 (5.9)

 

Epidermal growth factor receptor

351

 

Not significant

   Negative

292

26 (8.9)

 

   Positive

59

3 (5.1)

 

Basal markers [27]

455

 

Not significant

   Negative

311

31 (10.0)

 

   Positive

144

8 (5.6)

 

Nielsen groups [28]

396

 

Not significant

   HER2

39

3 (7.7)

 

   Basal-like

55

3 (5.5)

 

   Luminal

302

26 (8.6)

Â